enVVeno Medical (NASDAQ:NVNO) Earns Sell (D-) Rating from Weiss Ratings

enVVeno Medical (NASDAQ:NVNO)‘s stock had its “sell (d-)” rating restated by stock analysts at Weiss Ratings in a report issued on Saturday,Weiss Ratings reports.

Other equities analysts have also recently issued reports about the company. Wall Street Zen cut enVVeno Medical from a “hold” rating to a “sell” rating in a report on Saturday, August 9th. LADENBURG THALM/SH SH downgraded shares of enVVeno Medical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, enVVeno Medical presently has an average rating of “Reduce”.

enVVeno Medical Stock Performance

Shares of NASDAQ NVNO opened at $0.71 on Friday. The company has a market cap of $13.70 million, a PE ratio of -0.59 and a beta of 0.94. enVVeno Medical has a 52-week low of $0.67 and a 52-week high of $5.62. The firm’s 50 day moving average price is $1.01 and its 200-day moving average price is $2.88.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings results on Thursday, July 31st. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.05). On average, analysts forecast that enVVeno Medical will post -1.32 earnings per share for the current fiscal year.

Institutional Trading of enVVeno Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in enVVeno Medical in the 2nd quarter valued at $51,000. Creative Planning bought a new stake in shares of enVVeno Medical in the 2nd quarter worth about $54,000. XTX Topco Ltd bought a new stake in shares of enVVeno Medical in the 1st quarter worth about $80,000. Dauntless Investment Group LLC bought a new stake in shares of enVVeno Medical in the 1st quarter worth about $186,000. Finally, Geode Capital Management LLC increased its holdings in shares of enVVeno Medical by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after buying an additional 2,211 shares during the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Company Profile

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®?, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).